PaxMedica, Inc. Common Stock (PXMD)
Sector: Biotechnology
Industry: Biotechnology
PaxMedica, Inc. Common Stock
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 16, 2026 | 0.0005 | 0.0005 | 0.0005 | 0.0005 | 759 |
| Nov 11, 2026 | 0.0005 | 0.0007 | 0.0005 | 0.0007 | 569 |
| Nov 6, 2026 | 0.0005 | 0.0007 | 0.0005 | 0.0007 | 20,965 |
| Oct 23, 2026 | 0.0007 | 0.0007 | 0.0007 | 0.0007 | 3,500 |
| Oct 22, 2026 | 0.0005 | 0.0005 | 0.0005 | 0.0005 | 1,577 |
| Oct 14, 2026 | 0.0005 | 0.0005 | 0.0005 | 0.0005 | 257 |
| Oct 8, 2026 | 0.0007 | 0.0007 | 0.0007 | 0.0007 | 180 |
| Oct 7, 2026 | 0.0005 | 0.0005 | 0.0005 | 0.0005 | 117 |
| Oct 6, 2026 | 0.0007 | 0.0007 | 0.0007 | 0.0007 | 451 |
PaxMedica, Inc. is a biopharmaceutical company currently in the clinical development phase, dedicated to advancing anti-purinergic drug therapies (APTs). These innovative treatments are specifically designed to address complex neurological disorders presenting with stubborn and persistent symptoms.
The company's primary investigative drug is PAX-101, an intravenous (IV) form of suramin, which is being explored for a variety of conditions. These include autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, post-COVID-19 syndrome (commonly known as "long COVID"), and human African trypanosomiasis. Furthermore, PaxMedica is also developing PAX-102, an intranasal version of suramin, intended for various neurological applications.
The company, which was incorporated in 2018 and has its headquarters in Tarrytown, New York, previously operated as Purinix Pharmaceuticals LLC before rebranding to PaxMedica, Inc. in April 2020.
It functions as a subsidiary of Tardimed Sciences LLC.
No 13F filer reports a position yet. 13F reports are quarterly and are filed up to 45 days after the quarter ends.
30d Avg
5.47K
60d Avg
2.17K
90d Avg
3.41K
PaxMedica, Inc. Common Stock (OTC: PXMD) traded at $0.0005 on Nov 16, 2026. 52-week range: $0.0000 to $0.0080. The company is in the Healthcare sector (Biotechnology).